Brodalumab
Top View
- INN Working Document 05.179 Update 2011
- A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
- Inflammatory Conditions – Ilaris® (Canakinumab for Subcutaneous Injection)
- Pipeline: Respiratory, Inflammation & Autoimmunity (RIA) Inhaled Therapeutic Leadership; Spearheading Immunology Biologics
- (INN) for Biological and Biotechnological Substances
- Drug Therapy Advancements in Specialty Pharmacy Michael Mccall, Pharm.D
- Kevzara (Sarilumab)
- Siliq™ (Brodalumab for Subcutaneous Injection)
- WO 2018/067987 Al 12 April 2018 (12.04.2018) W !P O PCT
- RIA TA Strategy 2013
- 2017 Annual Review & Extract from Annual Report
- AZ Enters Licensing Agreements with LEO Pharma
- Targeted Immunomodulators for Plaque Psoriasis: Effectiveness and Value Condition Update Public Meeting – Morning Session July 12, 2018
- Defining the Role of Interleukin 17 in Rheumatoid Arthritis
- Emerging Therapeutic Options for the Treatment of Patients with Symptomatic Asthma R
- 1 Brodalumab in Psoriatic Arthritis: Results from the Randomised Phase
- Monoclonal Antibodies in Asthma
- Utah Medicaid Pharmacy and Therapeutics Committee Drug